For example, protective immunity is readily reactivated after drug cure;11 virally vectored antigen delivery generates effector CD8+ T cells and therapeutic benefit in rodents,30,38 and there have been encouraging data from human immunochemotherapy trials in leishmaniasis patients.16 The gene discussed is CD8A; the disease is leishmaniasis.